Cargando…

Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications

[Image: see text] Creating covalent protein conjugates is an active area of research due to the wide range of uses for protein conjugates spanning everything from biological studies to protein therapeutics. Protein Farnesyltransferase (PFTase) has been used for the creation of site-specific protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Dozier, Jonathan K., Khatwani, Santoshkumar L., Wollack, James W., Wang, Yen-Chih, Schmidt-Dannert, Claudia, Distefano, Mark D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103756/
https://www.ncbi.nlm.nih.gov/pubmed/24946229
http://dx.doi.org/10.1021/bc500240p
_version_ 1782327187224920064
author Dozier, Jonathan K.
Khatwani, Santoshkumar L.
Wollack, James W.
Wang, Yen-Chih
Schmidt-Dannert, Claudia
Distefano, Mark D.
author_facet Dozier, Jonathan K.
Khatwani, Santoshkumar L.
Wollack, James W.
Wang, Yen-Chih
Schmidt-Dannert, Claudia
Distefano, Mark D.
author_sort Dozier, Jonathan K.
collection PubMed
description [Image: see text] Creating covalent protein conjugates is an active area of research due to the wide range of uses for protein conjugates spanning everything from biological studies to protein therapeutics. Protein Farnesyltransferase (PFTase) has been used for the creation of site-specific protein conjugates, and a number of PFTase substrates have been developed to facilitate that work. PFTase is an effective catalyst for protein modification because it transfers Farnesyl diphosphate (FPP) analogues to protein substrates on a cysteine four residues from the C-terminus. While much work has been done to synthesize various FPP analogues, there are few reports investigating how mutations in PFTase alter the kinetics with these unnatural analogues. Herein we examined how different mutations within the PFTase active site alter the kinetics of the PFTase reaction with a series of large FPP analogues. We found that mutating either a single tryptophan or tyrosine residue to alanine results in greatly improved catalytic parameters, particularly in k(cat). Mutation of tryptophan 102β to alanine caused a 4-fold increase in k(cat) and a 10-fold decrease in K(M) for a benzaldehyde-containing FPP analogue resulting in an overall 40-fold increase in catalytic efficiency. Similarly, mutation of tyrosine 205β to alanine caused a 25-fold increase in k(cat) and a 10-fold decrease in K(M) for a coumarin-containing analogue leading to a 300-fold increase in catalytic efficiency. Smaller but significant changes in catalytic parameters were also obtained for cyclo-octene- and NBD-containing FPP analogues. The latter compound was used to create a fluorescently labeled form of Ciliary Neurotrophic Factor (CNTF), a protein of therapeutic importance. Additionally, computational modeling was performed to study how the large non-natural isoprenoid analogues can fit into the active sites enlarged via mutagenesis. Overall, these results demonstrate that PFTase can be improved via mutagenesis in ways that will be useful for protein engineering and the creation of site-specific protein conjugates.
format Online
Article
Text
id pubmed-4103756
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-41037562015-06-19 Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications Dozier, Jonathan K. Khatwani, Santoshkumar L. Wollack, James W. Wang, Yen-Chih Schmidt-Dannert, Claudia Distefano, Mark D. Bioconjug Chem [Image: see text] Creating covalent protein conjugates is an active area of research due to the wide range of uses for protein conjugates spanning everything from biological studies to protein therapeutics. Protein Farnesyltransferase (PFTase) has been used for the creation of site-specific protein conjugates, and a number of PFTase substrates have been developed to facilitate that work. PFTase is an effective catalyst for protein modification because it transfers Farnesyl diphosphate (FPP) analogues to protein substrates on a cysteine four residues from the C-terminus. While much work has been done to synthesize various FPP analogues, there are few reports investigating how mutations in PFTase alter the kinetics with these unnatural analogues. Herein we examined how different mutations within the PFTase active site alter the kinetics of the PFTase reaction with a series of large FPP analogues. We found that mutating either a single tryptophan or tyrosine residue to alanine results in greatly improved catalytic parameters, particularly in k(cat). Mutation of tryptophan 102β to alanine caused a 4-fold increase in k(cat) and a 10-fold decrease in K(M) for a benzaldehyde-containing FPP analogue resulting in an overall 40-fold increase in catalytic efficiency. Similarly, mutation of tyrosine 205β to alanine caused a 25-fold increase in k(cat) and a 10-fold decrease in K(M) for a coumarin-containing analogue leading to a 300-fold increase in catalytic efficiency. Smaller but significant changes in catalytic parameters were also obtained for cyclo-octene- and NBD-containing FPP analogues. The latter compound was used to create a fluorescently labeled form of Ciliary Neurotrophic Factor (CNTF), a protein of therapeutic importance. Additionally, computational modeling was performed to study how the large non-natural isoprenoid analogues can fit into the active sites enlarged via mutagenesis. Overall, these results demonstrate that PFTase can be improved via mutagenesis in ways that will be useful for protein engineering and the creation of site-specific protein conjugates. American Chemical Society 2014-06-19 2014-07-16 /pmc/articles/PMC4103756/ /pubmed/24946229 http://dx.doi.org/10.1021/bc500240p Text en Copyright © 2014 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html)
spellingShingle Dozier, Jonathan K.
Khatwani, Santoshkumar L.
Wollack, James W.
Wang, Yen-Chih
Schmidt-Dannert, Claudia
Distefano, Mark D.
Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
title Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
title_full Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
title_fullStr Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
title_full_unstemmed Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
title_short Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
title_sort engineering protein farnesyltransferase for enzymatic protein labeling applications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103756/
https://www.ncbi.nlm.nih.gov/pubmed/24946229
http://dx.doi.org/10.1021/bc500240p
work_keys_str_mv AT dozierjonathank engineeringproteinfarnesyltransferaseforenzymaticproteinlabelingapplications
AT khatwanisantoshkumarl engineeringproteinfarnesyltransferaseforenzymaticproteinlabelingapplications
AT wollackjamesw engineeringproteinfarnesyltransferaseforenzymaticproteinlabelingapplications
AT wangyenchih engineeringproteinfarnesyltransferaseforenzymaticproteinlabelingapplications
AT schmidtdannertclaudia engineeringproteinfarnesyltransferaseforenzymaticproteinlabelingapplications
AT distefanomarkd engineeringproteinfarnesyltransferaseforenzymaticproteinlabelingapplications